RAD50 and breast cancer: Extended mutation screening for RAD50 R385C using allele-specific real-time polymerase chain reaction (PCR) methodology excluded this rare variant in an additional 163 unrelated breast cancer patients stratified according to ER status (49 ER-negative, 114 ER-positive).